ERBB2 and breast cancer: The distribution of breast cancer subtypes was as follows: 310/780 patients (39.7%) had hormone receptor-positive, HER2-negative disease, 317/780 (40.6%) had TNBC, and 153/780 (19.6%) had HER2-positive disease (as previously reported23).